Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.080
-0.090 (-2.84%)
Feb 21, 2025, 4:00 PM EST - Market closed
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
99.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ANIX News
- 5 days ago - Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 9 days ago - Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview - PRNewsWire
- 12 days ago - Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum - PRNewsWire
- 19 days ago - Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention - PRNewsWire
- 4 weeks ago - Anixa Biosciences CEO Provides Letter to Shareholders - PRNewsWire
- 2 months ago - Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - PRNewsWire
- 3 months ago - Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset - PRNewsWire
- 3 months ago - Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire